Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
Regeneron Expands Deal With Intellia for Hemophilia Treatments
03:09pm, Tuesday, 02'nd Jun 2020
Regeneron (REGN) expands partnership with Intellia Therapeutics to co-develop potential hemophilia A and B treatments.
Stocks Still Rising to Begin June
01:15pm, Tuesday, 02'nd Jun 2020
Stocks Still Rising to Begin June
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) * Adaptimmune Therapeutics PLC - ADR (NASDAQ: ADAP) *
Regeneron, Intellia Expand Partnership To Develop Hemophilia Treatments
06:35am, Tuesday, 02'nd Jun 2020
Regeneron Pharmaceuticals, Inc (REGN) and Intellia Therapeutics, Inc. (NTLA) announced an expansion of their partnership to jointly develop potential products for the treatment of hemophilia A and B
Stocks Still Rising to Begin June
12:00am, Tuesday, 02'nd Jun 2020
Stocks Analysis by Zacks Investment Research covering: SPDR S&P 500, Electronic Arts Inc, Intercontinental Exchange Inc, Big Lots Inc. Read Zacks Investment Research's latest article on Investing.com
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
08:00pm, Monday, 01'st Jun 2020
Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today that it has
Xconomy: Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact
05:36pm, Monday, 01'st Jun 2020
Four years after Regeneron Pharmaceuticals and Intellia Therapeutics began working together to research the use of CRISPR/Cas9 to treat liver diseases,
Here's Why Intellia Therapeutics Gained as Much as 18.0% Today
03:46pm, Monday, 01'st Jun 2020
Shares of Intellia Therapeutics (NASDAQ: NTLA) rose as much as 18% today after the company announced an expansion of its partnership with Regeneron Pharmaceuticals (NASDAQ: REGN). The pair will joint
Regeneron to expand development deal with Intellia Therapeutics
11:57am, Monday, 01'st Jun 2020
Shares of Regeneron Pharmaceuticals Inc. undefined were down 0.5% in premarket trading on Monday after the company said it had expanded a collaboration with...
Regeneron to expand development deal with Intellia Therapeutics
11:57am, Monday, 01'st Jun 2020
Shares of Regeneron Pharmaceuticals Inc. were down 0.5% in premarket trading on Monday after the company said it had expanded a collaboration with Intellia Therapeutics Inc. to include CRISPR/Cas9-b
Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments
11:00am, Monday, 01'st Jun 2020
Regeneron and Intellia to co-develop potential hemophilia A and B treatments using their jointly-owned targeted transgene insertion capabilities
Here's Why Editas Could Beat Intellia to a CRISPR Therapy
11:39am, Friday, 22'nd May 2020
Editas has more favorable terms for its collaborations with big pharma companies, but it still has a long way to go.
The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray
12:00am, Friday, 22'nd May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 21)
ADC Therapeutics SA (NYSE:...
The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive
12:00am, Thursday, 21'st May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs on May 20.)
ADC Therapeutics SA (...
Consumer COVID-19 Tests Closer To Reality Under Mammoth Biosciences/GSK Partnership
04:00pm, Wednesday, 20'th May 2020
Mammoth Biosciences and GSK Consumer Healthcare are using CRISPR-based technology to develop an accurate, rapid and handheld test for COVID-19.
